Aarti Pharma Labs announced that Rajendra Vallabhaji Gogri, a Non-Executive Director, will not seek re-appointment at the company’s upcoming Annual General Meeting (AGM). The departure, driven by personal goals and other commitments, marks a change in the Board composition effective from the conclusion of the AGM.

Gogri, who holds Director Identification Number (DIN) 00061003, is liable to retire by rotation at the ensuing AGM. In a disclosure filed under Regulation 30 of the SEBI (LODR) Regulations, 2015, the company stated that Gogri informed management of his decision not to offer himself for re-election. Consequently, his tenure as a Director will continue only until the close of business hours on the date of the AGM.

The notification was submitted to the Listing/Compliance Departments of both BSE Ltd. and the National Stock Exchange of India Limited. Jeevan Bhargav Mondkar, Company Secretary and Legal Head of Aarti Pharmalabs Limited, signed the communication, confirming that the exchange records should be updated accordingly.

Key Details

The announcement does not specify an immediate replacement for Gogri. Shareholders will note the vacancy during the AGM proceedings, where the retirement by rotation process is typically finalized. The company’s Board will operate with this reduced membership until the AGM concludes, after which Gogri’s term officially ends.

Aarti Pharmalabs will host an earnings conference call on Monday, August 10, 2026, at 4:00 PM IST to discuss its Q1FY27 financial results. The event provides investors and analysts with a direct channel to review the company’s performance for the quarter ended June 30, 2026, and seek clarification on operational metrics. This disclosure ensures timely access to material information regarding the firm’s recent financial standing.

The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Aarti Pharmalabs submitted the intimation to the Listing/Compliance Departments of both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). Jeevan Bhargav Mondkar, Company Secretary and Legal Head, signed the communication on behalf of the board.

Management Participation

The management team representing Aarti Pharmalabs during the conference call includes senior leadership responsible for strategic and financial oversight. Investors can expect insights from the following executives:

Conference Call Details

The earnings call is being facilitated by 360 ONE Capital Market Research. Participants can join via the provided Diamond Pass link or through universal dial-in numbers available for domestic and international attendees. For further assistance, investors may contact Rohit Bhat or Maulik Varia at 360 ONE Capital Market Research.

What the Numbers Show

While specific financial figures for Q1FY27 are not detailed in this scheduling notice, the convening of the call signals the completion of the quarter’s reporting cycle. The participation of both the Chairman and the CFO suggests that the discussion will likely cover both strategic direction and detailed financial performance, offering a comprehensive view of the company’s position in the pharmaceutical sector for the period.